Ethan Russo, one of the world's leading physicians and experts in cannabis research, has been named chairman of the Scientific Council of Endocanna Health, a North American biotechnology company specializing in endocannabinoid DNA testing and precision cannabinoid formulations.
Russo will lead the Scientific Council on clinical research, both internally and with external partners.
“We are honored to have Dr. Russo as part of the EndoCanna team, leading our scientific research and clinical trials,” Len May, CEO and co-founder of Endocanna Health told GlobeNewsWire. "This is a crucial engagement for our company and our genome and cannabinoid research that will allow us to continue to refine our endodontically compatible product match."
Ethan Russo, who was in Portugal as a speaker at the Lisbon Medical Cannabis, in 2018, is the author of the most referenced cannabinoid study on PubMed regarding the entourage effect, and has driven cannabinoid research through his clinical studies. According to Endocanna Health, Ethan Russo's biography makes him the ideal addition to the company's Scientific Board, as he is a board-certified neurologist, psychopharmacology researcher and former senior medical consultant at GW Pharmaceuticals, where he served as a consultant for three clinical trials. Phase III of Sativex, a drug based on a complete extract of cannabis, indicated for the relief of the symptoms of Multiple Sclerosis (MS) and for the treatment of severe neuropathic pain related to cancer.
Prior to working at GW Pharmaceuticals, Russo was a clinical neurologist in Missoula, Montana for 20 years, with a practice in chronic pain. In 1995, he conducted a three-month sabbatical ethnobotanical survey with the Machiguenga tribe in Parque Nacional del Manu, Peru.
“I am pleased to partner with Endocanna Health and the promise that future research will shed light on the relationships between the endocannabinoid system and the human genome,” said Ethan Russo. “This type of research aims to contribute to the improvement of health and quality of life”.
The Endocanna Health Sciences Council was created earlier this year. Ethan Russo now joins Christopher Spooner, ND, Michael Tegan, and Len May, CEO of Endocanna Health, leading researchers in the field of cannabinoids and genomics. This team seeks to formalize the process that Endocanna Health currently uses to verify endocannabinoid, cannabinoid and genomic research to produce an Endo-Decoded consumer report and related endo-compatibility of products. The Council aims to examine in depth the integral role of plant medicine in modern therapeutics with regard to genomics, evaluating and recommending current and future research into cannabinoids and phytomedicines that Endocanna should involve, investigating the link between genotypes, cannabinoids and custom endo-compatibility.
______________________________________________________________________
Featured Image: Renato Velasco // Cannareporter